GLOBAL PARTNERJOHNSON & JOHNSON

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Background

HealthCare Royalty agreed to acquire a portion of royalties and milestones due to Nanobiotix from Johnson & Johnson in exchange for an upfront payment of $50 million plus an additional $21 million to be paid one year from closing subject to certain conditions. The transaction meaningfully extended Nanobiotix’s cash runway into early 2028, beyond key data readouts in head and neck cancer and lung cancer.

Note: This transaction also appears in the Corporate Financing section under Nanobiotix.